SanBio’s zero-revenue quarter hides the real shift: AKUGO now has a price, sales and a US Phase 3 path
The three months to April 30 produced no revenue and an ¥836 million net loss, yet AKUGO was added to Japan's reimbursement list in May at ¥72 million and commercial sales began. SanBio also said it agreed Phase 3 trial design with the FDA for traumatic brain injury, though the company did not disclose early sales volume or hospital uptake.